Case Report

68Ga-PSMA-11 PET-CT is superior to bone scintigraphy for detection bone metastasis in low and high grade of prostate cancer

Habibollah Dadgar

Habibollah Dadgar
Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran. Email: reza.lt.dadgar@gmail.com
Online First: April 03, 2019 | Cite this Article
Dadgar, H. 2019. 68Ga-PSMA-11 PET-CT is superior to bone scintigraphy for detection bone metastasis in low and high grade of prostate cancer. The Cancer Press 5(1, 2, 3, 4): 34-40. DOI:10.15562/tcp.72


Bone with distant metastasis and morbidity due to skeletal complications is a lesion that encouraged many authors to focus on the new radiotracers for better diagnosis regarding high sensitivity and specificity. However, 99mTc-Methylene diphosphonate (MDP) bone scintigraphy (BS) is the current standard imaging due to increase adsorption of the tracer at osteoblastic sites; it shows false-positives in degenerative changes and false-negatives in bone marrow metastasis. Recently, Prostate Specific Membrane Antigen (PSMA) is the promising target in prostate cancer imaging due to the over-expression in cancer cells. 68Ga-PSMA-11, a small molecule with PSMA enzyme inhibition activity has to benefit in bone and lymph-node recurrences and staging. Moreover, as degenerative changes do not have PSMA uptake will have not positive in response to therapy, the bone scan has enough quality for degenerative changes. With this consideration, BS is unable to differentiate bone metastasis from degenerative changes. 68Ga-PSMA-11 could overcome this limitation from conventional imaging as well. Finally, we concluded that PSMA PET-CT would have better sensitivity and specificity due to the unique distinction for detecting metastases. 

Keywords: bone scan, 68Ga-PSMA PET, metastasis

References

Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, et al. (2001) Whole-body MR imaging for detection of bone metastases in children and young adults: Comparison with skeletal scintigraphy and FDG PET. Am J Roentgenol 177: 229-236.

Cook GJ, Azad G, Padhani AR (2016) Bone imaging in prostate cancer: The evolving roles of nuclear medicine and radiology. Clin Transl Imaging 4: 439-447.

Wollin DA, Makarov DV (2015) Guideline of guidelines: Imaging of localized prostate cancer. BJU Int 116: 526-530.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, et al. (2014) EAU guidelines on prostate cancer. part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65: 124 -137.

Helyar V, Mohan HK, Barwick T, Clarke SE, Fogelman I, et al. (2010) The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 37: 706-713.

Even-Sapir E, Metser U, Mishani E, Lerman H, Lievssitz G, et al. (2006). The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287-97.

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3: 81-5.

Chang SS (2004) Overview of prostate-specific membrane antigen. Rev Urol 6: S13-S18.

Gupta M, Choudhury PS, Hazarika D, Rawal S (2017) A Comparative study of 68Gallium-prostate Specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: An initial experience. World J Nucl Med 16: 186-191.

Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Wester HJ, et al.(2015) Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 56:668-674.

Perera M, Papa N, Christidis D, Hofman MS, Bolton D, et al. (2016) Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur Urol 70: 926-937.

Pyka T, Okamoto S, Dahlbender M, Heck M, Eiber M, et al. (2016) Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 43: 2114-2121.

Schreiter V, Gericke M, Heimann U, Steffen I, Hamm B, et al. (2016) Comparison of [68Ga]Ga-PSMA-HBED-CC PET versus whole-body bone scintigraphy for the detection of bone metastases in patients with prostate cancer. J Nucl Med Radiat Ther 7: 302.

Lengana T, Modiselle M, Lawal I, Ebenhan T, Vorster M, et al. (2017) 68Ga-PSMA-PET/CT and bone scintigraphy imaging for staging of high- risk prostate cancer. J Nucl Med 58: 757.


No Supplementary Material available for this article.
Article Views      : 274
PDF Downloads : 128

Related Articles

Search Authors in












  • Habibollah Dadgar

  • Habibollah Dadgar

  • Habibollah Dadgar